Brokerages Set Carisma Therapeutics, Inc. (NASDAQ:CARM) Target Price at $4.94

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) have been given a consensus rating of “Hold” by the seven research firms that are covering the firm, MarketBeat reports. Five analysts have rated the stock with a hold recommendation, one has given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $4.94.

Several equities research analysts have recently commented on the company. HC Wainwright restated a “neutral” rating on shares of Carisma Therapeutics in a report on Monday, December 16th. D. Boral Capital decreased their price objective on Carisma Therapeutics from $24.00 to $12.00 and set a “buy” rating for the company in a report on Monday, December 9th. Robert W. Baird downgraded Carisma Therapeutics from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $10.00 to $1.00 in a report on Thursday, December 12th. BTIG Research downgraded Carisma Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, December 10th. Finally, EF Hutton Acquisition Co. I upgraded Carisma Therapeutics to a “strong-buy” rating in a report on Wednesday, October 30th.

Carisma Therapeutics Price Performance

Shares of CARM opened at $0.47 on Monday. Carisma Therapeutics has a 52-week low of $0.38 and a 52-week high of $2.94. The company has a debt-to-equity ratio of 1.39, a quick ratio of 3.23 and a current ratio of 3.23. The business’s 50 day moving average price is $0.71 and its two-hundred day moving average price is $0.94. The firm has a market cap of $19.79 million, a PE ratio of -0.30 and a beta of 1.56.

Carisma Therapeutics (NASDAQ:CARM) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.31). The firm had revenue of $3.39 million for the quarter. Carisma Therapeutics had a negative return on equity of 957.20% and a negative net margin of 314.78%. On average, equities analysts anticipate that Carisma Therapeutics will post -1.32 EPS for the current year.

Institutional Investors Weigh In On Carisma Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Wexford Capital LP grew its stake in Carisma Therapeutics by 75.5% in the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock valued at $34,000 after purchasing an additional 15,000 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in Carisma Therapeutics in the 2nd quarter valued at $40,000. Finally, Barclays PLC grew its stake in Carisma Therapeutics by 3,661,933.3% in the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after purchasing an additional 549,290 shares during the period. Institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.